Chronic blockade of gut beta-CGRP by mABs could theoretically contribute to modifying the physiological homeostasis of the intestinal mucosa in patients with inflammatory bowel diseases and, considering that there is a comorbidity between migraines and IBD [22], the status of IBD in patients with mAbs should be closely monitored. This evidence concerns the gene CALCB and irritable bowel syndrome.